# Cognition Therapeutics Inc: overview CGTX · Nasdaq · CIK 1455365 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cgtx.md) · [Financials](/companies/cgtx/financials.md) · [Filings](/companies/cgtx/filings.md) · [Insiders](/companies/cgtx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.25)](/filings/0001104659-25-107402.md) | not reported | [(0.14)](/filings/0001104659-26-057545.md) | [(0.11)](/filings/0001104659-26-092362.md) | [(0.06)](/filings/0001104659-25-107402.md) | not reported | [(0.05)](/filings/0001104659-26-057545.md) | [(0.04)](/filings/0001104659-26-092362.md) | | Free cash flow | $k | [(6,851) d](/filings/0001104659-25-107402.md) | [(8,383) d](/filings/0001104659-26-034880.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.13)](/filings/0001558370-23-004401.md) | [(0.91)](/filings/0001558370-24-003949.md) | [(0.86)](/filings/0001558370-25-003341.md) | [(0.86)](/filings/0001104659-26-034880.md) | [(0.32)](/filings/0001104659-26-034880.md) | | Free cash flow | $m | [(3.7)](/filings/0001558370-23-004401.md) | [(18.7)](/filings/0001558370-24-003949.md) | [(16.2)](/filings/0001558370-25-003341.md) | [(28.5)](/filings/0001104659-26-034880.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cgtx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BIOS Capital Management, LP](/funds/1813845.md) | 2026-06-30 | $6.9m | 6,000,000 | | Unchanged | | [DAVENPORT & Co LLC](/funds/887777.md) | 2026-06-30 | $4.9m | 4,259,511 | | Added +1,366,703 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.0m | 3,438,775 | | Added +436,988 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.5m | 1,261,993 | | Added +293,631 | | [Chescapmanager LLC](/funds/1697162.md) | 2026-06-30 | $1.1m | 997,029 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.0m | 910,006 | | Reduced −10,202 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $797.3k | 693,288 | | Reduced −423,848 | | [Hilton Capital Management, LLC](/funds/1541211.md) | 2026-06-30 | $631.3k | 548,950 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $584.5k | 508,220 | | Added +44,536 | | [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $517.5k | 450,000 | | Added +50,000 | ## Recent filings [All 301 filings](/companies/cgtx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 10:06 ET | [8-K](/filings/0001104659-26-117948.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-117948 | | 2026-08-07 | 11:30 ET | [10-Q](/filings/0001104659-26-092362.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092362 | | 2026-08-06 | 20:18 ET | [8-K](/filings/0001104659-26-092037.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-092037 | | 2026-06-24 | 11:39 ET | [8-K](/filings/0001104659-26-077060.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-077060 | | 2026-06-18 | 12:05 ET | [8-K](/filings/0001104659-26-075442.md) | 5.07 Shareholder vote results | 0001104659-26-075442 | | 2026-06-04 | 12:00 ET | [8-K](/filings/0001104659-26-070345.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-070345 | | 2026-05-21 | 11:34 ET | [8-K](/filings/0001104659-26-064863.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-064863 | | 2026-05-08 | 11:30 ET | [10-Q](/filings/0001104659-26-057545.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057545 | | 2026-05-07 | 20:24 ET | [8-K](/filings/0001104659-26-057186.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-057186 | | 2026-04-27 | 20:05 ET | [DEF 14A](/filings/0001104659-26-049427.md) | Proxy statement, period 2026-06-17 | 0001104659-26-049427 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-034880.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1455365 - Tickers: CGTX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.